Gender and BCR‐ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia
Achieving a major molecular response (MMR) is the goal of imatinib therapy for chronic myeloid leukemia. However, the association between gender, BCR‐ABL transcript type, and age with MMR is not well understood and often controversial.
No Supplementary Data
No Article Media